Published in PLoS Med on November 18, 2008
Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS One (2011) 2.00
The perils of PCR: can we accurately 'correct' antimalarial trials? Trends Parasitol (2010) 1.24
The effect of varying analytical methods on estimates of anti-malarial clinical efficacy. Malar J (2009) 0.84
Comparing highly efficacious antimalarial drugs. PLoS Med (2008) 0.84
The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature (2005) 31.73
Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med (2007) 13.43
Indicators of life-threatening malaria in African children. N Engl J Med (1995) 13.17
Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA (2006) 11.87
Trials to assess equivalence: the importance of rigorous methods. BMJ (1996) 9.29
Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother (1997) 7.36
The consequences of reducing transmission of Plasmodium falciparum in Africa. Adv Parasitol (2002) 6.01
Attributable fraction estimates and case definitions for malaria in endemic areas. Stat Med (1994) 5.58
The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. Malar J (2007) 4.85
Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet (2007) 4.85
Generation of allocation sequences in randomised trials: chance, not choice. Lancet (2002) 4.35
Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis (2007) 4.35
Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis (2006) 4.14
The past, present and future of childhood malaria mortality in Africa. Trends Parasitol (2001) 4.10
Innovative lead discovery strategies for tropical diseases. Nat Rev Drug Discov (2006) 3.87
Estimating the needs for artesunate-based combination therapy for malaria case-management in Africa. Trends Parasitol (2003) 3.21
Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial. Lancet (2004) 3.12
Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy! Acta Trop (2005) 3.08
Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet (2007) 2.99
In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrob Agents Chemother (2004) 2.77
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials (2007) 2.63
Antimalarial dosing regimens and drug resistance. Trends Parasitol (2008) 2.40
Genotyping of Plasmodium falciparum infections by PCR: a comparative multicentre study. Trans R Soc Trop Med Hyg (2001) 2.34
Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg (2003) 2.29
Design and analysis of non-inferiority mortality trials in oncology. Stat Med (2003) 2.24
Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malar J (2006) 2.19
A systematic overview of published antimalarial drug trials. Trans R Soc Trop Med Hyg (2004) 2.02
Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob Agents Chemother (2007) 2.02
Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. J Infect Dis (2007) 1.94
How antimalarial drug resistance affects post-treatment prophylaxis. Malar J (2008) 1.80
Pitfalls in estimating piperaquine elimination. Antimicrob Agents Chemother (2005) 1.79
Impact of transmission intensity on the accuracy of genotyping to distinguish recrudescence from new infection in antimalarial clinical trials. Antimicrob Agents Chemother (2007) 1.75
The use of genotyping in antimalarial clinical trials: a systematic review of published studies from 1995-2005. Malar J (2006) 1.73
Monitoring and deterring drug-resistant malaria in the era of combination therapy. Am J Trop Med Hyg (2007) 1.69
Distinguishing recrudescences from new infections in antimalarial clinical trials: major impact of interpretation of genotyping results on estimates of drug efficacy. Am J Trop Med Hyg (2005) 1.59
Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Lancet (2001) 1.58
World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs. Malar J (2007) 1.56
Intrahost selection of Plasmodium falciparum pfmdr1 alleles after antimalarial treatment on the northwestern border of Thailand. J Infect Dis (2006) 1.49
Methodological issues in the assessment of antimalarial drug treatment: analysis of 13 studies in eight African countries from 2001 to 2004. Antimicrob Agents Chemother (2006) 1.36
Risk associated with asymptomatic parasitaemia occurring post-antimalarial treatment. Trop Med Int Health (2008) 1.18
Complexity of Plasmodium falciparum infections and antimalarial drug efficacy at 7 sites in Uganda. J Infect Dis (2006) 1.11
Medicines for Malaria Venture: sustaining antimalarial drug development. Trends Parasitol (2006) 1.10
Can estimates of antimalarial efficacy from field studies be improved? Trends Parasitol (2008) 1.07
Effects of Plasmodium falciparum parasite population size and patient age on early and late parasitological outcomes of antimalarial treatment in children. Antimicrob Agents Chemother (2008) 1.01
Efficacy studies of malaria treatments in Africa: efficient estimation with missing indicators of failure. Stat Methods Med Res (2007) 0.80
Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2009) 33.25
The global distribution and population at risk of malaria: past, present, and future. Lancet Infect Dis (2004) 14.42
Typhoid fever. N Engl J Med (2002) 12.96
A world malaria map: Plasmodium falciparum endemicity in 2007. PLoS Med (2009) 12.82
Urbanization, malaria transmission and disease burden in Africa. Nat Rev Microbiol (2005) 11.88
Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2014) 11.87
Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet (2012) 11.82
Vivax malaria: neglected and not benign. Am J Trop Med Hyg (2007) 10.16
Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med (2004) 10.14
The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Med (2008) 8.95
Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet (2010) 8.52
Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. Lancet (2008) 8.50
Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. PLoS Med (2005) 8.36
Shrinking the malaria map: progress and prospects. Lancet (2010) 8.21
Effect of expanded insecticide-treated bednet coverage on child survival in rural Kenya: a longitudinal study. Lancet (2007) 7.98
Satellite imagery in the study and forecast of malaria. Nature (2002) 7.84
Climate change and the resurgence of malaria in the East African highlands. Nature (2002) 7.70
The decline in paediatric malaria admissions on the coast of Kenya. Malar J (2007) 7.45
Estimating the global clinical burden of Plasmodium falciparum malaria in 2007. PLoS Med (2010) 7.22
Improved diagnostic testing and malaria treatment practices in Zambia. JAMA (2007) 7.15
Assessment of inpatient paediatric care in first referral level hospitals in 13 districts in Kenya. Lancet (2004) 7.13
Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis (2012) 6.94
Increasing coverage and decreasing inequity in insecticide-treated bed net use among rural Kenyan children. PLoS Med (2007) 6.92
Insecticide-treated net coverage in Africa: mapping progress in 2000-07. Lancet (2008) 6.91
The burden of malaria mortality among African children in the year 2000. Int J Epidemiol (2006) 6.64
Measuring malaria endemicity from intense to interrupted transmission. Lancet Infect Dis (2008) 6.53
Operational strategies to achieve and maintain malaria elimination. Lancet (2010) 6.48
Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol (2006) 6.34
A major genome region underlying artemisinin resistance in malaria. Science (2012) 6.25
The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis (2010) 6.23
Mixed-species malaria infections in humans. Trends Parasitol (2004) 6.01
Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One (2009) 5.81
Scaling-up coverage with insecticide-treated nets against malaria in Africa: who should pay? Lancet Infect Dis (2003) 5.74
Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J (2011) 5.65
The malaria Atlas Project: developing global maps of malaria risk. PLoS Med (2006) 5.51
The effect of mobile phone text-message reminders on Kenyan health workers' adherence to malaria treatment guidelines: a cluster randomised trial. Lancet (2011) 5.42
Revisiting the basic reproductive number for malaria and its implications for malaria control. PLoS Biol (2007) 5.40
Forecasting, warning, and detection of malaria epidemics: a case study. Lancet (2003) 5.27
Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet (2013) 5.22
Quantifying the number of pregnancies at risk of malaria in 2007: a demographic study. PLoS Med (2010) 4.89
The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. Malar J (2007) 4.85
Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. PLoS Med (2005) 4.65
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med (2003) 4.64
Quantifying the impact of human mobility on malaria. Science (2012) 4.60
Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg (2007) 4.58
Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A (2010) 4.50
Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med (2005) 4.47
Manslaughter by fake artesunate in Asia--will Africa be next? PLoS Med (2006) 4.46
Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya. J Infect Dis (2005) 4.44
Mapping the global extent of malaria in 2005. Trends Parasitol (2006) 4.43
Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature (2012) 4.37
Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis (2007) 4.35
Population distribution, settlement patterns and accessibility across Africa in 2010. PLoS One (2012) 4.34
Access to artemisinin combination therapy for malaria in remote areas of Cambodia. Malar J (2008) 4.33
In vivo parasitological measures of artemisinin susceptibility. J Infect Dis (2010) 4.25
The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. Malar J (2009) 4.25
Negative epistasis between the malaria-protective effects of alpha+-thalassemia and the sickle cell trait. Nat Genet (2005) 4.22
Paediatric malaria case-management with artemether-lumefantrine in Zambia: a repeat cross-sectional study. Malar J (2007) 4.21
Delivery of paediatric care at the first-referral level in Kenya. Lancet (2004) 4.16
Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis (2006) 4.14
Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet (2004) 4.14
Measurement of trends in childhood malaria mortality in Africa: an assessment of progress toward targets based on verbal autopsy. Lancet Infect Dis (2003) 4.10
Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc Natl Acad Sci U S A (2012) 4.10
Early origin and recent expansion of Plasmodium falciparum. Science (2003) 4.07
Ranking of elimination feasibility between malaria-endemic countries. Lancet (2010) 4.05
Counterfeit anti-infective drugs. Lancet Infect Dis (2006) 3.91
Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet (2006) 3.90
Rickettsial infections and fever, Vientiane, Laos. Emerg Infect Dis (2006) 3.87
Standardizing estimates of the Plasmodium falciparum parasite rate. Malar J (2007) 3.87
High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in western Cambodia. J Infect Dis (2010) 3.81
Treatment of paediatric malaria during a period of drug transition to artemether-lumefantrine in Zambia: cross sectional study. BMJ (2005) 3.80
Malaria case-management under artemether-lumefantrine treatment policy in Uganda. Malar J (2008) 3.73
Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet (2004) 3.72
A selective sweep driven by pyrimethamine treatment in southeast asian malaria parasites. Mol Biol Evol (2003) 3.67
Defining and detecting malaria epidemics in the highlands of western Kenya. Emerg Infect Dis (2002) 3.55
Improving imperfect data from health management information systems in Africa using space-time geostatistics. PLoS Med (2006) 3.53
Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis (2002) 3.46
Impact of malaria during pregnancy on low birth weight in sub-Saharan Africa. Clin Microbiol Rev (2004) 3.45
Assembling a global database of malaria parasite prevalence for the Malaria Atlas Project. Malar J (2007) 3.42
Epidemiology of plasmodium-helminth co-infection in Africa: populations at risk, potential impact on anemia, and prospects for combining control. Am J Trop Med Hyg (2007) 3.29
Why don't health workers prescribe ACT? A qualitative study of factors affecting the prescription of artemether-lumefantrine. Malar J (2008) 3.25
Predicting changing malaria risk after expanded insecticide-treated net coverage in Africa. Trends Parasitol (2009) 3.25
Modelling distances travelled to government health services in Kenya. Trop Med Int Health (2006) 3.22
Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally. J Infect Dis (2010) 3.21
Malaria prevention in highland Kenya: indoor residual house-spraying vs. insecticide-treated bednets. Trop Med Int Health (2002) 3.20
Malaria misdiagnosis in Uganda--implications for policy change. Malar J (2009) 3.19
The use of formal and informal curative services in the management of paediatric fevers in four districts in Kenya. Trop Med Int Health (2003) 3.19
Effect of malaria rapid diagnostic tests on the management of uncomplicated malaria with artemether-lumefantrine in Kenya: a cluster randomized trial. Am J Trop Med Hyg (2009) 3.17
The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med (2005) 3.15
A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin Infect Dis (2005) 3.15
In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam. Malar J (2012) 3.13
How much fat is necessary to optimize lumefantrine oral bioavailability? Trop Med Int Health (2007) 3.13
Sickle cell trait and the risk of Plasmodium falciparum malaria and other childhood diseases. J Infect Dis (2005) 3.12
Hot topic or hot air? Climate change and malaria resurgence in East African highlands. Trends Parasitol (2002) 3.10
Climate change and the global malaria recession. Nature (2010) 3.10
Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis (2010) 3.08
The relationship between age and the manifestations of and mortality associated with severe malaria. Clin Infect Dis (2008) 3.05
How absolute is zero? An evaluation of historical and current definitions of malaria elimination. Malar J (2010) 3.05
Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis (2009) 3.05
Meteorologic influences on Plasmodium falciparum malaria in the Highland Tea Estates of Kericho, Western Kenya. Emerg Infect Dis (2002) 3.02